Summary
Unable to verify any extracted claims against the FDA-approved prescribing information because no label sections/text were provided.
Category Scores
Accurate Statements
Unsupported Statements
Empaveli (pegcetacoplan) is an oral brand of a Factor B inhibitor marketed in the United States.
No FDA label sections were provided to verify dosage form (oral), mechanism (Factor B inhibitor), or U.S. marketing/approval status.
Empaveli (pegcetacoplan) targets Factor B in the alternative complement pathway.
No FDA label sections were provided to support Factor B targeting and involvement of the alternative complement pathway.
Empaveli (pegcetacoplan) is marketed by Apellis Pharmaceuticals.
No FDA label sections were provided to verify the marketing authorization holder/manufacturer/distributor.
Empaveli (pegcetacoplan) is the primary branded oral Factor B inhibitor option referenced for the United States.
No FDA label sections were provided to support any comparative or 'primary' market-priority claim.
Contradictions
Important Omissions
FDA label text/sections were not supplied (e.g., Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Clinical Pharmacology, Manufacturer/Distributed by).
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
Because the prescribing information was not provided, the alignment of efficacy/safety-related labeling claims cannot be assessed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Assessable
Primary Issue
No FDA label sections/text were provided, so support/contradiction cannot be determined.
Suggested Improvement
Provide the relevant FDA-approved prescribing information sections (at minimum: Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Clinical Pharmacology/Mechanism of Action, and Manufacturer/Distributed by) so each extracted claim can be verified.